CD36 inhibition enhances the anti-proliferative effects of PI3K inhibitors in PTEN-loss anti-HER2 resistant breast cancer cells

Abstract Background HER2-positive patients comprise approximately 20% of breast cancer cases, with HER2-targeted therapy significantly improving progression-free and overall survival. However, subsequent reprogramed tumor progression due to PI3K signaling pathway activation by PIK3CA mutations and/o...

Full description

Saved in:
Bibliographic Details
Main Authors: You-Yu Liu, Wei-Lun Huang, Sin-Tian Wang, Hui-Ping Hsu, Tzu-Ching Kao, Wei-Pang Chung, Kung-Chia Young
Format: Article
Language:English
Published: BMC 2025-02-01
Series:Cancer & Metabolism
Subjects:
Online Access:https://doi.org/10.1186/s40170-025-00375-5
Tags: Add Tag
No Tags, Be the first to tag this record!